Kidney Week

Abstract: FR-PO056

University of California Irvine Supported Vascular Endothelial Growth Factor Inhibitor (Intravitreal) Systemic and Renal Toxicity Registry: 24-Month Update

Session Information

• AKI: Epidemiology, Risk Factors, and Prevention - 2
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

• 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

• Nguyen, Matthew Duy Thanh Luyen, University of California Irvine School of Medicine, Irvine, California, United States

Matthew Duy Thanh Luyen Nguyen

• Fekrat, Ryan Evan, University of California, Irvine - Department of Medicine, Irvine, California, United States

Ryan Evan Fekrat

• Nguyen, Vu Quy, University of California, Irvine - Department of Medicine, Irvine, California, United States

Vu Quy Nguyen

• Patel, Samir Dinesh, University of California Irvine Nephrology Hypertension & Kidney Transplantation, Orange, California, United States

Samir Dinesh Patel, MD, PhD

• Truong, Tai, University of California Irvine Nephrology Hypertension & Kidney Transplantation, Orange, California, United States

Tai Truong, MD

• Ahdoot, Rebecca S., University of California Irvine Nephrology Hypertension & Kidney Transplantation, Orange, California, United States

Rebecca S. Ahdoot

• Kurtz, Ira, University of California Los Angeles - Division of Nephrology, Los Angeles, California, United States

Ira Kurtz, MD, FASN

• Hanna, Ramy Magdy, University of California Irvine Nephrology Hypertension & Kidney Transplantation, Orange, California, United States

Ramy Magdy Hanna, MD, FASN

Background

Intravitreal Vascular Endothelial Growth Factor inhibitors (IVEGFi) are used in treatment of diabetic retinopathy. As we have previously reported there increasing number of cases documenting IVEGFi with renal injury and increased concentrations in the serum. To assess this claim, UCI Dept. of Nephrology has developed a novel reporting system through an electronic registry for cases of suspected VEGFi injury.

Methods

A website with data protection sets was organized to educate, promote awareness, and record cases of suspected intravitreal VEGFi toxicity. The website focused on displaying the biology of VEGF signaling, the process of absorption into the bloodstream, and the reporting of studies showing risks on case, cohort, and epidemiologic levels. A HIPAA compliant patient intake form was designed to collect renal, cardiovascular, cerebrovascular, renal biopsy and function data along with drug type, indication, and frequency of administration.

Results

In our updated cohort we added 17 total cases from the literature showing signs of renal injury from the patient population receiving VEGFi. In current literature, 46 cases of VEGFi related renal injury have been documented. To them we add our 17 cases for a total of 63 cases.

Conclusion

The current database for VEGFi related nephrotoxicity constitutes the largest case series presented for this condition. This study suggests future studies to evaluate what subgroups experience AKI, proteinuria and HTN exacerbations. Additionally, we may expand on our database to include timeline markers for symptomatic-correlative VEGFi usage and, in time, predictive measures in larger scale to correlate comorbidity/drug use with drug effect and mechanism of action.